PROTAC, abbreviated as proteolysis-targeting chimeras, is a hybrid bifunctional small molecule compound composed of three parts: target protein ligand, E3 ligase ligand, and a linker connecting the two ligands. Thus forming a ternary complex (target protein ligand-Linker-E3 ligase ligand). After the PROTAC molecule enters the cell, the target protein ligand binds to the target protein, and the E3 ubiquitin ligase ligand binds to the substrate binding region of the E3 ubiquitin ligase. Through Linker, the target protein and E3 ubiquitin ligase are "brought closer" to each other, and the target protein is specifically degraded through the ubiquitin proteasome pathway. The concept of PROTAC was first proposed by Crews et al. in 2001. After 20 years of continuous improvement and development, it has become one of the hottest technologies in the field of new drug research and development.
Based on the nearly 10 years of accumulation of Medinoah in the PROTAC field, Abosyn has developed over 500 unique products, including:
1.CRBN ligand series
2.VHL ligand series
3.Linker product series,
4.E3 ligase ligand-linker modular product
PROTAC product customization services (can meet the integrated and multi-dimensional needs from research and development to production)